Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | The role of venetoclax in older patients with AML

Andrew Wei • 25 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies APR-246 Azacitidine Checkpoint inhibitors Cytarabine Magrolimab Venetoclax
VIALE-A VIALE-C

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, outlines the role of venetoclax in older patients with acute myeloid leukemia (AML). Dr Wei highlights the phase III studies, VIALE-A (NCT02993523) and VIALE-C (NCT03069352), of venetoclax in combination with azacitidine or low-dose cytarabine. Additionally, he also discusses primary and adaptive resistance to venetoclax-based combinations associated with FLT3 and TP53 mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals